NCT04633967

Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

Completed Last updated 13 March 2024

What this trial tests

trial testing Alemtuzumab Injection in Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis in 30 participants. Completed in 28 February 2021.

Timeline

15 May 2016

Primary endpoint
30 December 2020

28 February 2021

Quick facts

Lead sponsor	Maritime Neurology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	15 May 2016
Primary completion	30 December 2020
Estimated completion	28 February 2021
Sites	1 location across Canada

Drugs / interventions tested

• Alemtuzumab Injection — full drug profile →

Conditions studied

• Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis — all drugs for Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis →

Sponsor

Maritime Neurology — full company profile →

Who can join

Adults 18 to 65, any sex, with Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen.
   Leckey R, Borsellino L, Rawlings AM, Ashkenas J, et al · · 2022 · cited 3× · PMID 35870368 · DOI 10.1016/j.msard.2022.104030